Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, USA.
Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, USA.
J Clin Anesth. 2013 Aug;25(5):379-383. doi: 10.1016/j.jclinane.2013.01.014. Epub 2013 Aug 17.
To compare analgesia and opioid-related side effects of intrathecal morphine and intrathecal hydromorphone after elective Cesarean delivery.
Retrospective, comparative study.
Labor and delivery unit of an academic hospital.
114 parturients age ≥ 18 years, presenting for elective Cesarean delivery.
Patients who received 0.04 mg intrathecal hydromorphone were compared to a random sample of patients who received 0.1 mg intrathecal morphine for postoperative analgesia.
The primary outcome was the presence of any opioid-related complication (pruritus, nausea or vomiting, respiratory depression) requiring treatment within 24 hours of intrathecal opioid administration. Secondary outcomes included total opioid consumption (in oral morphine equivalents) within 24 hours of intrathecal opioid administration and verbal pain score (0 = none, 10 = worst) at 4, 8, 12, 18, and 24 hours after intrathecal opioid administration.
38 patients who received intrathecal hydromorphone 0.04 mg were compared with 76 patients given 0.1 mg of intrathecal morphine for elective Cesarean delivery. No significant differences in demographics were noted between groups. There were no statistically significant differences between the intrathecal hydromorphone and intrathecal morphine groups in overall frequency of opioid-related complications (50% vs. 34.2%; P = 0.11), 24-hour opioid consumption (33 mg oral morphine equivalent [OME] vs. 8 mg OME; P = 0.27), or pain scores at any time point up to 24 hours.
Overall, analgesia and incidence of opioid-related side effects after 0.04 mg of intrathecal hydromorphone did not differ statistically from 0.1 mg of intrathecal morphine.
比较择期剖宫产术后鞘内注射吗啡和氢吗啡酮的镇痛效果和阿片类药物相关副作用。
回顾性比较研究。
学术医院的产房和分娩单位。
114 名年龄≥18 岁的产妇,择期行剖宫产术。
比较接受 0.04mg 鞘内氢吗啡酮和随机选择的接受 0.1mg 鞘内吗啡用于术后镇痛的患者。
主要结局是鞘内阿片类药物给药后 24 小时内是否存在任何需要治疗的阿片类药物相关并发症(瘙痒、恶心或呕吐、呼吸抑制)。次要结局包括鞘内阿片类药物给药后 24 小时内的总阿片类药物消耗量(以口服吗啡当量计)和鞘内阿片类药物给药后 4、8、12、18 和 24 小时的口头疼痛评分(0=无,10=最差)。
38 例接受鞘内氢吗啡酮 0.04mg 的患者与 76 例接受 0.1mg 鞘内吗啡的患者进行了比较,用于择期剖宫产。两组患者的人口统计学特征无显著差异。鞘内氢吗啡酮组和鞘内吗啡组在阿片类药物相关并发症的总体发生率(50%比 34.2%;P=0.11)、24 小时阿片类药物消耗量(33mg 口服吗啡当量[OME]比 8mg OME;P=0.27)或任何时间点(至 24 小时)的疼痛评分均无统计学差异。
总体而言,鞘内注射 0.04mg 氢吗啡酮的镇痛效果和阿片类药物相关副作用的发生率与鞘内注射 0.1mg 吗啡无统计学差异。